Zentalis Pharmaceuticals
ZNTL
116 hedge funds and large institutions have $2.75B invested in Zentalis Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 59 increasing their positions, 29 reducing their positions, and 18 closing their positions.
6,541% more call options, than puts
Call options by funds: $28.8M | Put options by funds: $434K
103% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 29
29% more capital invested
Capital invested by funds: $2.13B → $2.75B (+$618M)
3% less funds holding
Funds holding: 120 → 116 (-4)
5.41% less ownership
Funds ownership: 96.98% → 91.57% (-5.4%)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.2M |
| 2 |
BlackRock
New York
|
+$25.1M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$19.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.1M |
| 5 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$22.6M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$16.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.51M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$4.84M |
ZNTL Hedge Fund Activity: Q3 2021 in Review
116 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2021, worth a combined $2.75B — up 29% from $2.13B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ZNTL and 15 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 59 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $27.2M. The largest seller was Redmile Group, exiting entirely with an estimated $22.6M sold.
- 116 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2021, down from 120 in Q2 2021.
- Funds reported $2.75B of Zentalis Pharmaceuticals stock for Q3 2021, up 29% quarter-over-quarter.
- 15 funds opened new Zentalis Pharmaceuticals positions in Q3 2021 and 18 closed out, a net change of -3 holders.
- The largest Zentalis Pharmaceuticals buyer in Q3 2021 was T. Rowe Price Associates, an estimated $27.2M added.
- The largest Zentalis Pharmaceuticals seller in Q3 2021 was Redmile Group, an estimated $22.6M sold.
Based on aggregated 13F filings for Q3 2021.